Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled dose-selection study in which two
doses of nangibotide are tested versus placebo.
All patients with a diagnosis of septic shock will be considered for study participation. All
potential study patients will receive standard of care for the treatment of septic shock.
After screening for eligibility, patients meeting all inclusion and no exclusion criterion
will be randomized. Patients will be randomized to one of three treatment arms.
Treatment with study drug must be initiated as early as possible, but no later than 24 hours
after the onset of septic shock, defined by the start of vasopressor therapy.
Patients will be treated for at least 3 days with study drug. After the first 3 days of
treatment, patients still requiring vasopressor will be treated until 24 hours after
vasopressor withdrawal with a maximum treatment duration of 5 days.
Patients will be assessed at the End of Study (EoS) visit at day 28. After the last patient's
day 28 visit, the study will be analyzed. Additional follow up (FU) visits will be conducted
after 90 days, 6 and 12 months.
The objective of the study ist to compare the safety, tolerability and efficacy of two doses
of nangibotide versus placebo, when given in addition to standard of care.